BEHAVIORAL
Early intervention programme
For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
Chasing Biomarkers in Post-concussion Syndrome
Status
Completed
Phase
Not applicable
Enrollment
86
Locations
0
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The goal of this study was to investigate the biomarkers, neurofilament light chain, inflammatory markers, calcitonin-gene-related peptide, and metabolites from the kynurenine pathway in patients with severe post-concussive symptoms. The main question it aimed to answer was: * Are the biomarker concentrations significantly changed in patients with severe post-concussive symptoms compared to healthy individuals? * Do the biomarker concentrations change at follow-up? Participants were recruited from a recently published randomized controlled trial (Clinicaltrials.gov no. NCT02337101 / PMID: 31891145 ). The biomarker concentrations were compared to a healthy control group recruited from the Blood Bank at Aarhus University Hospital in 2022.
Full detailed description
In the previously published RCT-study (PMID: 31891145), 86 participants with severe post-concussive symptoms provided blood samples at baseline (4 months after the concussion). Severe post-concussive symptoms were defined as having a Rivermead Post Concussion Questionnaire \>20. Around 7 months later, a follow-up blood sample was obtained from 54 participants. These blood samples were used to investigate blood biomarkers for the condition.
Interventions
Treatment arms and agents.
BEHAVIORAL
Enhanced usual care
For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
Timeline
From registration to results.
First posted
Apr 14, 2023
Study start
Mar 2015
Primary completion
Jul 2023
Study completion
Jul 2023
Results posted
Not reported
Registry updated
Apr 16, 2024
Outcomes
What the study measures.
Primary outcomes
Neurofilament light chain at baseline (primary outcome)
Time frame · The baseline blood sample was taken up to 7 months after the concussion (4 months median).
The investigators hypothesized: The concentration of neurofilament light chain (ng/L) is significantly increased at baseline in patients compared to the healthy control group.
Neurofilament light chain at follow-up (primary outcome)
Time frame · The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample.
The investigators hypothesized: 1)The neurofilament light chain concentration (ng/L) normalizes (decreases) at follow-up compared to the baseline concentration in patients.
Self-reported post-concussion symptoms score (primary outcome)
Time frame · The baseline symptom score (RPQ) was obtained from the patients up to 7 months after the concussion (4 months median), and the follow-up score was obtained up to 16 months (10.5 median) after the concussion
The symptom score was measured at both baseline and follow-up using the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) which is a self-reported questionnaire. The Rivermead Post-Concussion Symptoms Questionnaire contains 16 items which is rated from 0 (not experienced) to 4 (a severe problem). The total score thus ranges on a scale between 0-64.
Calcitonin-gene related peptide at baseline (CGRP)
Time frame · The baseline blood sample was taken up to 7 months after the concussion (4 months median).
The investigators hypothesized: The concentration of calcitonin gene-related peptide (pg/mL) is decreased compared to the healthy control group at baseline
Calcitonin-gene related peptide at follow-up (CGRP)
Time frame · The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample.
The investigators hypothesized: The CGRP concentrations (pg/mL) will normalize (increase) at follow-up compared to baseline.
Secondary outcomes
Quinolinic acid at baseline
Time frame · The baseline blood sample was taken up to 7 months after the concussion (4 months median).
The investigators hypothesized that: The concentration of the neurotoxic metabolite, quinolinic acid (measured in nM), is increased in patients compared to healthy controls
Quinolinic acid at follow-up
Time frame · The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample.
The investigators hypothesized: The quinolinic acid concentration (nM) normalizes (decreases) at follow-up compared to the baseline concentration.
Neuroprotective index at baseline
Time frame · The baseline blood sample was taken up to 7 months after the concussion (4 months median).
The investigators hypothesized: The ratio between the neuroprotective metabolite kynurenic acid (KYNA) and the neurotoxic metabolite quinolinic acid (KynA/QUIN) is lower than the ratio in healthy individuals at baseline. A higher ratio means a better outcome.
Neuroprotective index at follow-up
Time frame · The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample.
The investigators hypothesized: The ratio between the neuroprotective metabolite kynurenic acid (KYNA) and the neurotoxic metabolite quinolinic acid (QUIN) normalizes (increases) at follow-up compared to baseline. A higher ratio thus means a better outcome.
Inflammatory markers at baseline
Time frame · The baseline blood sample was taken up to 7 months after the concussion (4 months median).
The investigators hypothesized that: Tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) (both pg/mL) are increased in patients compared to healthy controls.
Inflammatory markers at baseline
Time frame · The baseline blood sample was taken up to 7 months after the concussion (4 months median).
The investigators hypothesized: Basic fibroblast growth factor (Basic FGF), Eotaxin, interferon gamma (IFN-y), interleukin 1 beta (IL-1B), interleukin 8 (IL-8), interleukin 9 (IL-9), interleukin 17 (IL17), Interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), and Macrophage Inflammatory Protein beta (MIP-1b) (all pg/mL) are significantly increased in patients compared to controls (hypothesis is based on a recent study (PMID: 32326805)
Inflammatory markers at follow-up
Time frame · The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample.
TNF-α and IL-6 (both pg/mL) decreases at follow-up compared to the baseline value in patients.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 30 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Patients with severe post-concussive symptoms: Inclusion Criteria: 1. Concussion caused by a head trauma based on the diagnostic criteria recommended by the World Health Organization (WHO) Task Force 2. Age between 18 and 30 years 3. Able to understand, speak and read Danish. 4. A score of 20 or more on the Rivermead Post Concussion Symptoms Questionnaire (RPQ). Exclusion Criteria: 1. Objective neurological findings indicating neurological disease or brain damage. 2. Previous concussion leading to persistent post-concussional symptoms within the last two years. 3. Severe misuse of alcohol, prescription drugs and / or illegal drugs. 4. Severe psychiatric, neurological,or other medical disease that would impede participation in the intervention 5. Inability to speak and read Danish Healthy control group (recruited from December 2021 - March 2022): \- Individuals from the Blood Bank at Aarhus University Hospital in Denmark. Inclusion criteria were: 1. Age between 18-30 years 2. Equal distribution between the genders (60 men and 60 women). This number was based on a power analysis using published data from neurofilament light chain.
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Calcitonin.
NCT IDStudyPhase / statusEnrollmentUpdated
Long-term Atogepant in Real-world Practice
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Migraine · Headache
Not applicable
Completed
513
2026-07
Different Kinematics Within a Single-File System and Postoperative Pain
Jordan University of Science and Technology · Root Canal Treatment · Postoperative Pain
Not applicable
Active, not recruiting
75
2026-07
Subcutaneous Calcitonin in Acute Herpes Zoster
Tanta University · Calcitonin · Subcutaneous
Phase 3
Recruiting
168
2026-07
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
Insel Gruppe AG, University Hospital Bern · Acute Mountain Sickness
Phase 4
Not yet recruiting
30
2026-07
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
Institut Claudius Regaud · Medullary Thyroid Cancer
Not applicable
Completed
24
2026-06
Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension
Rigmor Højland Jensen · Idiopathic Intracranial Hypertension (IIH)
Phase 3
Not yet recruiting
96
2026-06
i-NEED: NEw migrainE Drugs Database
IRCCS San Raffaele Roma · Episodic Migraine · Chronic Migraine
Not applicable
Recruiting
2,641
2026-06
Mulligan Mobilization and Stabilization Exercises for Sensorimotor Function in Women With Text Neck Syndrome
Pamukkale University · Neck Pain · Text Neck Syndrome
Not applicable
Completed
38
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.